ClinicalTrials.gg
CompletedNCT07231978Updated May 14, 2026

A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

A Phase 1 interventional study of Prazosin HCl in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Prazosin hydrochloride (HCl) is a medicine taken by mouth that helps lower high blood pressure. It's used to treat hypertension, as well as heart failure. The purpose of this clinical trial is to prove that the prazosin HCl capsules made at the manufacturing site at Barceloneta (Puerto Rico) work the same in the body, as those made at Ascoli (Italy). This will be done by understanding how the different capsules and doses of prazosin HCL are changed and eliminated from your body after you take them. The study will also check how safe these capsules are and how well people can handle them.

This study is seeking participants ≥ 18 years old, who are healthy and have a total body weight >50 kg (110 lb). Before starting, participants will be interviewed and examined by skilled personnel to make sure they qualify. This will happen up to 28 days before the first dose of the study drug. Those who are eligible will check into the clinical research unit (CRU) the day before first dose of the study drug and stay there until 24 hours after their last dose [for approximately 9 days and 8 nights for cohort (group) 1 and 5 days and 4 nights for cohort (group) 2].

While in CRU each participant will receive by mouth either 4 capsules (cohort 1) or 2 capsules (cohort 2) of prazosin HCL at different time points. The capsules will be taken with a glass of water after overnight fasting. No food is allowed until 4 hours after taking the dose. Water is allowed freely except for 1 hour before dosing and can be consumed again 1 hour after dosing. Blood samples will be taken from participants right before they take the medicine and again after they have taken it. Electrocardiogram and blood pressure will be closely monitored.

We will compare the experiences of people receiving capsules manufactured at Barceloneta to those manufactured at Ascoli. This will help us determine if capsules from Barceloneta and Ascoli are safe and effective.

After completing all tests, participants will leave the CRU. Then, about 28 to 35 days after their final dose, they'll receive a follow-up phone call to check on their health.

The total duration of participation from the initial ("screening") visit to discharge from the CRU will be approximately 5 weeks and from the initial visit to follow up phone call will be approximately 10 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants, 18 years of age or older and who are overtly healthy as determined by medical evaluation
  • Willing to comply with all study procedures
  • of 16-32 kg/m2; and a total body weight >50 kg (110 lb)
  • Capable of giving signed

Exclusion criteria

Exclusion:

  • Evidence or history of disease
  • Evidence of any active suicidal ideation in the past year or suicidal behavior in the past 5 years
  • Use of drugs within 14 days or 5 half-lives (whichever is longer) prior to study intervention
  • Previous administration of an product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive a single dose of Prazosin HCl in 4 treatments.

    Drug: Prazosin HCl

  • Experimental
    Cohort 2

    Participants will receive a single dose of Prazosin HCl in 2 treatments.

    Drug: Prazosin HCl

Interventions

  • Administered Orally; available in capsule form

    Also known as: CP-012299

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area under the plasma concentration (AUC) of prazosin

    Time frame: Predose, upto 5 weeks

  2. PK: Maximum plasma concentration (Cmax) of prazosin

    Time frame: Predose, upto 5 weeks

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Through study completion, approximately 10 weeks

  2. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Through study completion, approximately 10 weeks

  3. Number of participants with change from baseline in physical examinations

    Time frame: Through study completion, approximately 10 weeks

  4. Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Parameters

    Time frame: Through study completion, approximately 10 weeks

  5. Number of Participants With Abnormalities in Vital Signs

    Time frame: Through study completion, approximately 10 weeks

07

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région de B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Apr 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Nov 14, 2025
Primary completionActual
Apr 3, 2026
CompletionActual
Apr 30, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07231978
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 14, 2025
Primary completion
Apr 3, 2026
Completion
Apr 30, 2026
Last update
May 14, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prazosin

Start the discussion